Sign In

Saiid Zarrabian

President & CEO at Kintara Therapeutics, Inc.

Saiid Zarrabian, based in San Diego, California, is a prominent figure in the biopharmaceutical industry, currently serving as the President and CEO of Kintara Therapeutics, a company dedicated to developing and commercializing innovative cancer therapies.

Kintara Therapeutics focuses on understanding tumor biology and treatment resistance mechanisms to personalize new therapies, particularly for patients with limited treatment options or low tolerability to standard treatments.

The company's pipeline revolves around VAL-083, a groundbreaking small-molecule chemotherapeutic with a unique mechanism targeting various cancers such as central nervous system, ovarian, NSCLC, bladder, and head & neck tumors.

VAL-083 is being studied in clinical trials, including MGMT-unmethylated GBM trials, addressing significant unmet medical needs by overcoming treatment resistance in GBM.

In addition to VAL-083, Kintara Therapeutics is embarking on a Phase 3 study with REM-001 for Cutaneous Metastatic Breast Cancer, further expanding their innovative treatment portfolio.

Saiid Zarrabian's extensive career includes leadership roles in various pharmaceutical companies such as DelMar Pharmaceuticals, Immune Therapeutics, Cyntellect, Senomyx, and Molecular Simulations, among others, showcasing his wealth of experience and expertise in the industry.

Saiid Zarrabian
Add to my network

Location

Rancho Santa Fe, California